EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia

Kavyesh Vivek iD, Zekiye Karagozlu, Simon Erridge iD, Carl Holvey, Ross Coomber, James J Rucker, Mark W Weatherall, Mikael H Sodergren

Brain and Behavior · 2024

DOI: 10.1002/brb3.3410 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain and Behavior, 2024. Verfasst von Kavyesh Vivek und 7 weiteren Autor:innen. Beteiligte Einrichtung: Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Medical Marijuana, Cannabis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The primary aim of this study was to assess changes in sleep‐specific health‐related quality of life (HRQoL) for those prescribed cannabis‐based medicinal products (CBMPs) for insomnia.

Methods

A case series of UK patients with insomnia was analyzed. Primary outcomes were changes in the Single‐Item Sleep‐Quality Scale (SQS), Generalized Anxiety Disorder‐7 (GAD‐7), and EQ‐5D‐5L at up to 6 months from baseline. Statistical significance was identified as a p value < .050.

Results

61 patients were included in the analysis. There was an improvement in the SQS from baseline at 1, 3, and 6 months ( p < .001). There were also improvements in the EQ‐5D‐5L Index value and GAD‐7 at 1, 3, and 6 months ( p < .050). There were 28 (45.9%) adverse events recorded by 8 patients (13.1%). There were no life‐threatening/disabling adverse events.

Conclusion

Patients with insomnia experienced an improvement in sleep quality following the initiation of CBMPs in this medium‐term analysis. Fewer than 15% of participants reported one or more adverse events. However, due to the limitations of the study design, further investigation is required before definitive conclusions can be drawn on the efficacy of CBMPs in treating insomnia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Initiation and Maintenance DisordersMedical MarijuanaCannabisHumansQuality of LifeRegistriesUnited Kingdom

Stichwörter der Autor:innen

benzodiazepinescannabis-based medicinal productsinsomniasleep quality

Substanzen

Medical Marijuana

Autor:innen und Institutionen

  • Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.
  • Department of Medicine, Curaleaf Clinic, London, UK.
  • Department of Trauma and Orthopaedics, St. George's Hospital NHS Trust, London, UK.
  • Department of Psychological Medicine, Kings College London, London, UK.
  • National and Specialist Tertiary Referrals Affective Disorders Service, South London & Maudsley NHS Foundation Trust, London, UK.
  • Department of Neurology, Buckinghamshire Healthcare NHS Trust, Amersham, UK.

ORCID-Profile: Kavyesh Vivek, Simon Erridge

Zitieren

APA

Vivek, K., Karagozlu, Z., Erridge, S., Holvey, C., Coomber, R., Rucker, J. J., Weatherall, M. W., & Sodergren, M. H. (2024). UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia. Brain and Behavior. https://doi.org/10.1002/brb3.3410

Vancouver

Vivek K, Karagozlu Z, Erridge S, Holvey C, Coomber R, Rucker JJ, et al. UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia. Brain and Behavior. 2024. doi:10.1002/brb3.3410

BibTeX
@article{Vivek2024,
  author = {Vivek, Kavyesh and Karagozlu, Zekiye and Erridge, Simon and Holvey, Carl and Coomber, Ross and Rucker, James J and Weatherall, Mark W and Sodergren, Mikael H},
  title = {UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia},
  journal = {Brain and Behavior},
  year = {2024},
  doi = {10.1002/brb3.3410}
}
Kostenlos starten →